Our CEO, David Longo, and CSO, Ziwei Liang, had the great opportunity to talk with Genetic Engineering & Biotechnology News on the exciting opening of our Ordaōs lab space in New York, how it will support our R&D efforts & capabilities in mini-protein design, and how the fusion of AI in biotech is re-shaping the drug discovery process as we know it. Read the article here: https://hubs.li/Q01-R2cl0
Ordaos Bio’s Post
More Relevant Posts
-
CEO @ Ordaos Bio. Intelligent Drug Design Factory Builder. Harvard Biotech. Stanford AI/ML. MIT Sloan EDP.
Powerful innovations in #Biotech are helping breathe new life into people, products, and the planet. Ordaos Bio's work is featured in Deloitte's new #xTech Futures: BioTech report! https://deloi.tt/3KPxOgb
Trends in Biotechnology
www2.deloitte.com
-
CEO @ Ordaos Bio. Intelligent Drug Design Factory Builder. Harvard Biotech. Stanford AI/ML. MIT Sloan EDP.
So grateful to have represented Ordaos Bio at BIO Korea this month in Seoul! Witnessing Korea's commitment to the tech bio revolution was truly inspiring. The collaboration between Johnson & Johnson Innovation and the Republic of Korea's Ministry of Health & Welfare is set to drive growth and globalization in this field. Excited for Ordaos to be part of JLABS Korea! Huge thanks to Sharon Chan, Melinda Richter, Jesse Hwang, Tingting Zhang-Kharas, PhD, and everyone involved for this incredible opportunity. Ordaos continues accelerating the reduction of disease burden globally with groundbreaking technology. #BIOKorea #TechBio #Innovation #Ordaos #JLabsKorea #JohnsonandJohnsonInnovation 🌏💉🔬
-
-
Attending BIO Partnering at JPM Week? Click below to send Ordaos a meeting request in the BIO partnering system! #JPM2024 https://hubs.li/Q02f932V0 We look forward to seeing you next week in San Francisco.
-
-
Our CEO, David Longo, was a guest speaker on Daniel Levine's podcast, The BIO Report, to discuss Ordaōs' groundbreaking work in drug development, the advantages mini-proteins have over traditional antibodies, and how our generative AI platform is leading an industry-wide shift in biotech from drug discovery to drug design. Listen in to learn more: https://hubs.li/Q025Hs9H0
Using AI to Generate Mini-Protein Therapeutics | The Bio Report
thebioreport.podbean.com
-
Ordaos is #hiring! We're looking for a Backend Engineer II to be a part of our ongoing mission to create bespoke mini-proteins to enable ground-breaking therapeutics. 🚀 Apply here: https://lnkd.in/ednhuXE3 #biotechjobs #techjobs
-
